The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Abstract
Purpose: In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III trial to our knowledge combining bevacizumab with chemotherapy in platinum-resistant OC. Patients and Methods: Eligible patients had measurable/assessable OC that had progressed < 6 months after completing platinum-based therapy. Patients with refractory disease, history of bowel obstruction, or > two prior anticancer regimens were ineligible. After investigators selected chemotherapy (pegylated liposomal doxorubicin, weekly paclitaxel, or topotecan), patients were randomly assigned to single-agent chemotherapy alone or with bevacizumab (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks) until progression, unacceptable toxicity, or consent withdrawal. Crossover to single-agent bevacizumab was permitted after progression with chemotherapy alone. The primary end point was progression-free survival (PFS) by RECIST. Secondary end points included objective response rate (ORR), overall survival (OS), safety, and patient-reported outcomes. Results: The PFS hazard ratio (HR) after PFS events in 301 of 361 patients was 0.48 (95% CI, 0.38 to 0.60; unstratified log-rank P < .001). Median PFS was 3.4 months with chemotherapy alone versus 6.7 months with bevacizumab-containing therapy. RECIST ORR was 11.8% versus 27.3%, respectively (P = .001). The OS HR was 0.85 (95% CI, 0.66 to 1.08; P < .174; median OS, 13.3 v 16.6 months, respectively). Grade ≥ 2 hypertension and proteinuria were more common with bevacizumab. GI perforation occurred in 2.2% of bevacizumab-treated patients. Conclusion: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant. No new safety signals were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
Self-citationAghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211
Bennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166
Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5345 · Cited by 882
Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0782 · Cited by 759
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
ten Bokkel Huinink, W., Gore, M., Carmichael, J., Gordon, A., Malfetano, J., Hudson, I., Broom, C., Scarabelli, C., Davidson, N., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 663
Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., Groshen, S., Swenson, S., Markland, F., Gandara, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1939 · Cited by 547
Mutch, D. G., Orlando, M., Goss, T., Teneriello, M. G., Gordon, A. N., McMeekin, S. D., Wang, Y., Scribner, D. R., Marciniack, M., Naumann, R. W., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6735 · Cited by 426
Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
Stockler, M. R., Hilpert, F., Friedlander, M., King, M. T., Wenzel, L., Lee, C. K., Joly, F., de Gregorio, N., Arranz, J. A., Mirza, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4240 · Cited by 178
Self-citationManagement strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Sehouli, J., Stengel, D., Oskay-Oezcelik, G., Zeimet, A. G., Sommer, H. L., Klare, P., Stauch, M. B., Paulenz, A., Camara, O., Keil, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1258 · Cited by 137
Kobold, S., Hegewisch‐Becker, S., Oechsle, K., Jordan, K., Bokemeyer, C., & Atanackovic, D. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0109 · Cited by 107
Vergote, I. B., Finkler, N. J., Campo, J.-M. D., Lohr, A., Hunter, J. E., Matei, D. E., Kavanagh, J. J., Vermorken, J. B., Meng, L., Jones, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.05.016 · Cited by 101
Self-citationLortholary, A. H., Largillier, R., Weber, B. E., Gladieff, L., Alexandre, J., Durando, X., Slama, B., Dauba, J., Paraiso, D., & Pujade-Lauraine, É. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr149 · Cited by 91
Self-citationSimpkins, F. A., Belinson, J. L., & Rose, P. G. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.06.004 · Cited by 81
Buda, A. A., Floriani, I., Rossi, R., Colombo, N., Torri, V., Conte, P., Fossati, R., Ravaioli, A., & Mangioni, C. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601787 · Cited by 80
McGonigle, K. F., Muntz, H. G., Vuky, J., Paley, P. J., Veljovich, D. S., Greer, B. E., Goff, B. A., Gray, H. J., & Malpass, T. W. (2011) · Cancer · doi:10.1002/cncr.25967 · Cited by 78
Richardson, D. L., Backes, F. J., Hurt, J. D., Seamon, L. G., Copeland, L. J., Fowler, J. M., Cohn, D. E., & O’Malley, D. M. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.011 · Cited by 46
Update of randomized trials in recurrent disease
Pujade-Lauraine, É., & Alexandre, J. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr518 · Cited by 24
Naumann, R. W., Gilbert, L., Miller, A. M., Ma, H., Ghamande, S. A., & Vergote, I. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.tps5613 · Cited by 11
Self-citation
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationEpithelial ovarian cancer: Evolution of management in the era of precision medicine
Lheureux, S., Braunstein, M., & Oza, A. M. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21559 · Cited by 1,423
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citation
Metadata
- Authors
- Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., Pereira, D., Wimberger, P., Oaknin, A., Mirza, M. R., Follana, P., Bollag, D., & Ray-Coquard, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-05-01
- Volume
- 32
- Issue
- 13
- Pages
- 1302-1308
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2170928115
- Cited by
- 1,622
- References
- 23
- FWCI
- 153.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.